CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

People with certain types of long-term sleep disorders feel extremely tired during the day, a condition known as excessive daytime sleepiness (EDS). There are many medicines that work in different ...

When is the worst time of day to take a nap? Avoid napping during this time window, which may disrupt sleep and cause side ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

UC San Francisco study finds women over 80 who experience increased daytime sleepiness face twice the risk of developing ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Given sleep’s profound impact on well-being, unexplained daytime fatigue and disrupted sleep patterns necessitate a ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Axsome Therapeutics (AXSM) announced results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder, MDD, ...

If you have a long-term sleep disorder that causes excessive daytime sleepiness (EDS), you may need to take medicines to manage your symptoms. The different medicines available for these ...